DRE Treatment for Adults - VNS Therapy Epilepsy

Studies have shown that VNS Therapy^™ is an effective treatment option

No “honeymoon effect” with VNS Therapy™ ²

Change from baseline in total number of seizures per week was significantly greater with VNS Therapy + BMP vs BMP only (p=0.03)

Change from baseline in total number of seizures per week was significantly greater with VNS Therapy™ + Best Medical Practice (BMP) vs Best Medical Practice (BMP) only (p=0.03)

Seizure reduction that continues to improve over time³

Seizure frequency significantly reduced from baseline at each recorded interval over 10 years (p<0.001) in patients with partial and generalized seizures

A retrospective study that followed 65 patients (14% of the study population) that undergo 10 years of VNS Therapy™

VNS Therapy™ significantly reduces Depressive Symptoms in Patients with Drug-Resistant Epilepsy

VNS Therapy™ is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)⁵

Accidents and injuries reduced post-VNS Therapy™

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy™ compared to pre-VNS Therapy™ periods⁶

Improved alertness, mood and memory in DRE patients treated with VNS Therapy™ ^7,8

Head Trauma

Fractures

Emergency Room Visits

Hospitalisations

Number of Hospital Days

VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time^4,10

Safety Profile

VNS Therapy^™ has no drug interactions and does not cause drug-related toxic central nervous system side effects.¹¹

The most common adverse events following stimulation (>5%) were voice alterations, increased coughing, pharyngitis, paresthesia, dyspnea, dyspepsia, and nausea. These side effects typically occur only during stimulation and generally become less noticeable over time for most patients.^1,10,11

Infection is the most common complication of the surgical procedure. Children (<12 years of age) may have a greater risk for infection when compared to adolescent and adult patients (≥12 years).¹

For more safety information click here.

References

1. VNS Therapy™ System Epilepsy Physician’s Manual (OUS), January 2025, LivaNova, Houston, TX. 2. Ryvlin P, et al. Epilepsia. 2014;55(6):893–900. 3. Elliott RE, et al. Epilepsy Behav. 2011;20(3):478–83. 4. Elliott RE, et al. Epilepsy Behav. 2011;20(1):57–63. 5. Spindler, et al. Seizure. 2019;69:77–9. 6. Helmers SL. Epilepsy Behav. 2011;22(2):370–5. 7. Orosz I, et al. Epilepsia. 2014;55(10):1576–84. 8. Englot DJ, et al. Epilepsy Behav. 2017;66:4–9. 9. Data on File. CORE-VNS Clinical Study Report, LivaNova, USA, June 2025. 10. Ben-Menachem E. J Clin Neurophysiol. 2011;18(5):415–8. 11. VNS Therapy™ Patient's Guide for Epilepsy (OUS), January 2025, LivaNova, Houston, TX.

VNS Therapy™ treatment in adult patients

Studies have shown that VNS Therapy^™ is an effective treatment option

VNS Therapy™ requires a less invasive implantation procedure than other implantable devices for DRE⁴

Beyond seizures, VNS Therapy™ may reduce the impact of comorbidities in patients with drug-resistant epilepsy

In DRE, comorbidities are significant contributors to a reduced quality of life

VNS Therapy™ is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)⁵

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy™ compared to pre-VNS Therapy™ periods⁶

Improved alertness, mood and memory in DRE patients treated with VNS Therapy™ ^7,8

VNS Therapy™ can help reduce hospitalisations and healthcare resource utilisation events^6,9

CORE-VNS